Sequential therapy with daunorubicin and L-asparaginase in relapses of acute lymphoblastic leukemia in children

13 children affected by acute lymphoblastic leukemia in advanced stage of illness received a sequential therapy with daunorubicin and L-asparaginase. During daunorubicin therapy a significant decrease of bone hypercellularity as well as circulating cells occurred, a further cycle with a scarcely myelotoxic drug, L-asparaginase, was administered: a 10/13 (76.9%) remission of the disease was then achieved. This therapeutic trial was well accepted and could be more extensively used in the patients in relapse. A remission lasting between 4 and 28 weeks was observed.